Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Ror1-positive mesenchymal stem cell-containing pharmaceutical composition for preventing or treating disease associated with fibrosis, method for preparing same, and method for preventing or treating disease associated with fibrosis using ror1-positive mesenchymal stem cells

A technology of mesenchymal stem cells and treatment methods, applied in the direction of medical preparations containing active ingredients, drug combinations, biochemical equipment and methods, etc., can solve the problem that the therapeutic effect of mesenchymal stem cells cannot be said to be sufficient

Inactive Publication Date: 2019-11-05
ROHTO PHARM CO LTD
View PDF10 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the therapeutic effect of these mesenchymal stem cells cannot be said to be sufficient

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Ror1-positive mesenchymal stem cell-containing pharmaceutical composition for preventing or treating disease associated with fibrosis, method for preparing same, and method for preventing or treating disease associated with fibrosis using ror1-positive mesenchymal stem cells
  • Ror1-positive mesenchymal stem cell-containing pharmaceutical composition for preventing or treating disease associated with fibrosis, method for preparing same, and method for preventing or treating disease associated with fibrosis using ror1-positive mesenchymal stem cells
  • Ror1-positive mesenchymal stem cell-containing pharmaceutical composition for preventing or treating disease associated with fibrosis, method for preparing same, and method for preventing or treating disease associated with fibrosis using ror1-positive mesenchymal stem cells

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0107] [Preparation of ROR1-positive mesenchymal stem cells]

[0108] The method for preparing ROR1-positive mesenchymal stem cells is not particularly limited, and can be prepared, for example, as follows. That is, mesenchymal stem cells are isolated from umbilical cord, adipose tissue, bone marrow and other tissues according to methods known to those skilled in the art and cultured, and ROR1 is isolated by using an anti-ROR1 antibody that specifically binds to ROR1 through a cell sorter, magnetic beads, etc. Positive cells can thus be obtained. In addition, ROR1-positive mesenchymal stem cells can also be obtained by inducing the expression of ROR1 in mesenchymal stem cells by culturing using a medium described later. In the cell cluster obtained by this induction, preferably 70% or more of the cell cluster are ROR1-positive, more preferably 80% or more are ROR1-positive, still more preferably 90% or more are ROR1-positive, and particularly preferably substantially uniform ...

Embodiment

[0207] Next, the present invention will be described more specifically by way of examples, but the present invention is not limited by the following examples.

[0208]

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The purpose of the present invention is to provide the following: novel mesenchymal stem cells having an excellent therapeutic effect on various diseases, particularly diseases associated with fibrosis; and a pharmaceutical composition containing such mesenchymal stem cells. The present invention is a therapeutic agent for fibrosis that contains ROR1-positive mesenchymal stem cells and / or a culture supernatant thereof and that is for preventing or treating a disease associated with fibrosis. The mesenchymal stem cells are CD29-, CD73-, CD90-, CD105-, and CD166-positive and are preferably derived from the umbilical cord or fat. In addition, the abovementioned disease associated with fibrosis is preferably a liver disease, a lung disease, a kidney disease, or a heart disease.

Description

technical field [0001] The present invention relates to a pharmaceutical composition for preventing or treating diseases accompanied by fibrosis containing ROR1-positive mesenchymal stem cells, a preparation method thereof, and prevention of diseases accompanied by fibrosis using ROR1-positive mesenchymal stem cells or disposal method. Background technique [0002] In recent years, drug development and regenerative medical research using cells or tissues of living organisms are advancing and attracting attention. Among them, ES cells and iPS cells are being rapidly researched as organ regeneration technology or drug discovery and screening tools. On the other hand, cell therapy that isolates and uses somatic stem cells (mesenchymal stem cells) from bone marrow, adipose tissue, umbilical cord, etc., uses adult stem cells in regenerative medicine to repair tissues damaged by diseases, etc. Since it is inherently functional, it has attracted attention and been researched as a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K35/28A61K35/51A61P1/16A61P9/04A61P9/10A61P11/00A61P13/12
CPCA61K35/28A61P1/16A61P9/04A61P9/10A61P11/00A61P13/12C12N5/0667C12N2501/392C12N2501/415C12N2501/727C12N2501/60C12N2501/70C12N2501/998C12N2501/115C12N5/0668C12N2500/25
Inventor 长谷川辉汤本真代池山芳史西田浩之津田智博宇野荣子须田一真吉野美穗子吴春忠
Owner ROHTO PHARM CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com